XFOR Company Profile and Key Details
NASDAQ : XFOR
X4 Pharmaceuticals
$3.40
-0.04-1.16%
At Close 4:00 PM61.68
BESG ScoreESG Rating
Price Chart
Stock Price Today
X4 Pharmaceuticals, Inc. (XFOR) stock declined over -1.16%, trading at $3.40 on NASDAQ, down from the previous close of $3.44. The stock opened at $3.32, fluctuating between $3.23 and $3.40 in the recent session.
Stock Snapshot
3.44
Prev. Close
38.79M
Market Cap
3.23
Day Low
-0.38
P/E Ratio
-8.92
EPS (TTM)
-0.46
Cash Flow per Share
3.32
Open
11.41M
Number of Shares
3.4
Day High
71.51%
Free Float in %
0.26
Book Value
267.02K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 02, 2026 | 3.32 | 3.44 | 3.24 | 3.40 | 267.02K |
| Feb 27, 2026 | 3.25 | 3.44 | 3.20 | 3.43 | 792.97K |
| Feb 26, 2026 | 3.43 | 3.53 | 3.21 | 3.25 | 829.47K |
| Feb 25, 2026 | 3.39 | 3.56 | 3.39 | 3.44 | 978.06K |
| Feb 24, 2026 | 3.17 | 3.43 | 3.14 | 3.39 | 221.94K |
| Feb 23, 2026 | 3.12 | 3.25 | 3.10 | 3.16 | 251.79K |
| Feb 20, 2026 | 3.05 | 3.19 | 3.01 | 3.16 | 322.22K |
| Feb 19, 2026 | 2.97 | 3.15 | 2.96 | 3.10 | 571.19K |
| Feb 18, 2026 | 3.10 | 3.12 | 2.83 | 2.99 | 1.08M |
| Feb 17, 2026 | 3.40 | 3.42 | 3.09 | 3.10 | 642.18K |
| Feb 13, 2026 | 3.39 | 3.51 | 3.38 | 3.41 | 160.76K |
| Feb 12, 2026 | 3.49 | 3.49 | 3.14 | 3.37 | 539.44K |
| Feb 11, 2026 | 3.69 | 3.78 | 3.43 | 3.43 | 428.44K |
| Feb 10, 2026 | 3.53 | 3.76 | 3.52 | 3.71 | 603.04K |
| Feb 09, 2026 | 3.57 | 3.63 | 3.53 | 3.55 | 194.71K |
| Feb 06, 2026 | 3.70 | 3.82 | 3.52 | 3.56 | 831.78K |
| Feb 05, 2026 | 3.78 | 3.83 | 3.65 | 3.66 | 621.72K |
| Feb 04, 2026 | 3.99 | 4.00 | 3.75 | 3.85 | 999.12K |
| Feb 03, 2026 | 3.98 | 4.00 | 3.80 | 4.00 | 463.48K |
| Feb 02, 2026 | 3.66 | 4.00 | 3.66 | 3.98 | 385.51K |
Contact Details
About Company
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenstr�m macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Company Information
| Employees | 143 |
| Beta | 0.43 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
9.14+1.17%
Regeneron Pharmaceuticals, Inc.$790.81ARGX-10.16-1.32%
argenx SE$756.76UTHR9.92+1.97%
United Therapeutics Corporation$513.82VRTX-10.8-2.17%
Vertex Pharmaceuticals Incorporated$486.03MDGL3.62+0.84%
Madrigal Pharmaceuticals, Inc.$435.62PRAX-6.16-1.83%
Praxis Precision Medicines, Inc.$330.59KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-7.85-2.36%
Alnylam Pharmaceuticals, Inc.$325.07KRYS-16.83-6.11%
Krystal Biotech, Inc.$258.81ASND8.59+3.68%
Ascendis Pharma A/S$242.09Company Overview
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) closed at $3.40 USD, losing -$0.04 (-1.16%) from the previous close of $3.44. The stock is currently mid-range between its 52-week high and low $1.35 and $12.54. With a market capitalization of about $38.79 million, X4 Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 598.93 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, X4 Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adam R. Craig, the company employs approximately 143 people and listed since November 16, 2017. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 -6.47%, SMA50 -12.52%, SMA200 1.61%). The stock’s 14-day RSI is 42.39 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.98% below its high and over 140.74% above its low. Average 10-day trading volume of 523.35 thousand shares is below the 3-month average of 592.73 thousand, indicating normal recent market interest.
Dividend & Fair Value
X4 Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.22. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
X4 Pharmaceuticals, Inc. generated EPS of -$10.01 over the past year. Five-year average earnings growth is 47.41%. Wall Street analysts project EPS growth of 48.4% annually over the next five years. The latest quarter delivered EPS of -$0.69. The next quarter is forecast at -$0.25. Next year's EPS is expected at $34.15. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $1.50. The high target offers 194.12% upside. The low target suggests -55.88% downside. The mean target is $5.33. This offers 56.76% upside. X4 Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 56.59%. The prior quarter beat by -23.4%. Over the last six quarters, Apple has recorded several small beats. These include -1004.8% in August 08, 2024.
Shareholding & Insider Activity
X4 Pharmaceuticals, Inc. has 22.45 million shares outstanding. The public float is 8.16 million shares, elevated short interest at 6.95% of float. This equals 1.55 million shares. The short ratio is 0.17 days. Institutional investors hold 31.34% of the float. Insiders own 1.15%. SVLSF V, LLC holds 1.85 million shares, Ragan Paula has 1.09 million shares and Nessi Claudio has 867.64 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.
Frequently Asked Questions
What is the current X4 Pharmaceuticals, Inc. (XFOR) stock price?
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) stock price is $3.40 in the last trading session. During the trading session, XFOR stock reached the peak price of $3.40 while $3.23 was the lowest point it dropped to. The percentage change in XFOR stock occurred in the recent session was -1.16% while the dollar amount for the price change in XFOR stock was - $0.04.
XFOR's industry and sector of operation?
The NASDAQ listed XFOR is part of Biotechnology industry that operates in the broader Healthcare sector. X4 Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of XFOR?
Dr. Robert David Arbeit
Senior Vice President of Clinical Devel. and Translational Research
Dr. Keith T. Flaherty M.D.
Founder & Member of Corporation Advisory Board
Mr. Mark Baldry M.B.A.
Chief Commercial Officer
Dr. Mary DiBiase Ph.D.
Chief Operating Officer
Dr. Richard Peters M.D., Ph.D.
Founder
Dr. Murray W. Stewart M.D.
Interim Chief Medical Officer & Director
Dr. Renato T. Skerlj Ph.D.
Founder
Dr. Arthur Taveras Ph.D.
Chief Scientific Officer
Mr. Adam S. Mostafa
Managing Director
Dr. Paula Ragan Ph.D.
Chief Executive Officer, Pres & Director
Senior Vice President of Clinical Devel. and Translational Research
Dr. Keith T. Flaherty M.D.
Founder & Member of Corporation Advisory Board
Mr. Mark Baldry M.B.A.
Chief Commercial Officer
Dr. Mary DiBiase Ph.D.
Chief Operating Officer
Dr. Richard Peters M.D., Ph.D.
Founder
Dr. Murray W. Stewart M.D.
Interim Chief Medical Officer & Director
Dr. Renato T. Skerlj Ph.D.
Founder
Dr. Arthur Taveras Ph.D.
Chief Scientific Officer
Mr. Adam S. Mostafa
Managing Director
Dr. Paula Ragan Ph.D.
Chief Executive Officer, Pres & Director
How XFOR did perform over past 52-week?
XFOR's closing price is 151.85% higher than its 52-week low of $1.35 where as its distance from 52-week high of $12.54 is -72.89%.
How many employees does XFOR have?
Number of XFOR employees currently stands at 143.
Link for XFOR official website?
Official Website of XFOR is: https://www.x4pharma.com
How do I contact XFOR?
XFOR could be contacted at phone 857 529 8300 and can also be accessed through its website. XFOR operates from 61 North Beacon Street, Boston, MA 02134, United States.
How many shares of XFOR are traded daily?
XFOR stock volume for the day was 267.02K shares. The average number of XFOR shares traded daily for last 3 months was 598.93K.
What is the market cap of XFOR currently?
The market value of XFOR currently stands at $38.79M with its latest stock price at $3.40 and 11.41M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep